logo

VTGN

Vistagen·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

VTGN fundamentals

Vistagen (VTGN) released its earnings on Nov 13, 2025: revenue was 258.00K (YoY 0.00%), beat estimates; EPS was -0.54 (YoY 0.00%), missed estimates.
Revenue / YoY
258.00K
0.00%
EPS / YoY
-0.54
0.00%
Report date
Nov 13, 2025
VTGN Earnings Call Summary for Q2,2026
  • Trial Milestone: PALISADE-3 Phase III trial completed; top-line results expected by end of 2025.
  • Cash Position: $77.2 million in cash to support U.S. registration efforts.
  • Pipeline Expansion: itruvone and PH80 in Phase III, targeting depression and menopause.
  • Commercial Focus: Exploring partnerships for U.S. launch, leveraging digital health trends.
  • FDA Readiness: Preparing for potential NDA submission in early 2026.
EPS
Revenue

Revenue & Expenses

VTGN has released its 2026 Q2 earnings report, with revenue of 258.00K, reflecting a YoY change of 40.98%, and net profit of -19.42M, showing a YoY change of -49.81%. The Sankey diagram below clearly presents VTGN's revenue sources and cost distribution.

Key Indicators

Vistagen (VTGN) key financial stats and ratios, covering profitability, financial health, and leverage.
Vistagen (VTGN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Vistagen (VTGN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Vistagen (VTGN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Vistagen (VTGN) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Vistagen (VTGN) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield